Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Review Article

抗癌肽（ACP）在肝细胞癌治疗中的潜在用途

卷 20, 期 3, 2020

页: [187 - 196] 页: 10

弟呕挨: 10.2174/1568009619666191111141032

价格: $65

摘要

肽作为有前途的治疗剂，尤其是近年来作为抗癌替代物，已引起越来越多的兴趣。据报道，由于它们的低制造成本，易于合成以及高度的特异性和选择性，它们显示出令人难以置信的抗癌潜力。肝细胞癌（HCC）是全球癌症死亡的主要原因之一，目前的肝脏治疗有效性已成为有效治疗该疾病的关键问题。因此，正在探索用于治疗肝细胞癌的新干预措施。抗癌肽（ACP）首先被鉴定为生命有机体固有免疫系统的一部分，证明其对传染病具有广阔的前景。不同于传统上对内源性人类肽的研究，肽药物的发现已发展为更多地依赖于与其他天然来源的分离或通过药物化学方法。迄今为止，由于肽具有许多优点，例如相对于正常组织的针对癌症的高选择性和有效性，以及广泛的抗癌活性，制药行业打算进行更多的临床试验以开发作为替代疗法的肽。在本文中，我们概述了有关肽的理化性质的文献，并描述了目前参与肝细胞癌临床试验的几种抗癌肽的当代状态。

关键词: 肝细胞癌，肝癌，抗癌肽，临床试验，耐药性，治疗性肽。

« Previous Next »
[1]
Pushpanathan, M.; Gunasekaran, P.; Rajendhran, J. Antimicrobial peptides: Versatile biological properties. Int. J. Pept., 2013, 2013, 675391
[http://dx.doi.org/10.1155/2013/675391] [PMID: 23935642]
[2]
Seo, M-D.; Won, H-S.; Kim, J-H.; Mishig-Ochir, T.; Lee, B-J.; Seo, M-D.; Won, H-S.; Kim, J-H.; Mishig-Ochir, T.; Lee, B-J. Antimicrobial peptides for therapeutic applications: A review. Molecules, 2012, 17(10), 12276-12286.
[http://dx.doi.org/10.3390/molecules171012276] [PMID: 23079498]
[3]
Bahar, A.A.; Ren, D. Antimicrobial peptides. Pharmaceuticals (Basel), 2013, 6(12), 1543-1575.
[http://dx.doi.org/10.3390/ph6121543] [PMID: 24287494]
[4]
Felício, M.R.; Silva, O.N.; Gonçalves, S.; Santos, N.C.; Franco, O.L. Peptides with dual antimicrobial and anticancer activities. Front Chem., 2017, 5, 5.
[http://dx.doi.org/10.3389/fchem.2017.00005] [PMID: 28271058]
[5]
Wu, D.; Gao, Y.; Qi, Y.; Chen, L.; Ma, Y.; Li, Y. Peptide-based cancer therapy: Opportunity and challenge. Cancer Lett., 2014, 351(1), 13-22.
[http://dx.doi.org/10.1016/j.canlet.2014.05.002] [PMID: 24836189]
[6]
Deslouches, B.; Di, Y.P. Antimicrobial peptides with selective antitumor mechanisms: Prospect for anticancer applications. Oncotarget, 2017, 8(28), 46635-46651.
[http://dx.doi.org/10.18632/oncotarget.16743] [PMID: 28422728]
[7]
Lee, C-S.; Taib, N.A.M.; Ashrafzadeh, A.; Fadzli, F.; Harun, F.; Rahmat, K.; Hoong, S.M.; Abdul-Rahman, P.S.; Hashim, O.H. Unmasking heavily O-glycosylated serum proteins using perchloric acid: Identification of serum proteoglycan 4 and protease C1 inhibitor as molecular indicators for screening of breast cancer. PLoS One, 2016, 11(2), e0149551
[http://dx.doi.org/10.1371/journal.pone.0149551] [PMID: 26890881]
[8]
Le, C-F.; Fang, C-M.; Sekaran, S.D. Intracellular targeting mechanisms by antimicrobial peptides. Antimicrob. Agents Chemother., 2017, 61(4), e02340-e16.
[http://dx.doi.org/10.1128/AAC.02340-16] [PMID: 28167546]
[9]
Tirla, A.; Rivera-Fuentes, P. Peptide targeting of an intracellular receptor of the secretory pathway. Biochemistry, 2019, 58(9), 1184-1187.
[http://dx.doi.org/10.1021/acs.biochem.9b00029] [PMID: 30785735]
[10]
Teixeira, V.; Feio, M.J.; Bastos, M. Role of lipids in the interaction of antimicrobial peptides with membranes. Prog. Lipid Res., 2012, 51(2), 149-177.
[http://dx.doi.org/10.1016/j.plipres.2011.12.005] [PMID: 22245454]
[11]
Lee, E.; Koskimaki, J.E.; Pandey, N.B.; Popel, A.S. Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Neoplasia, 2013, 15(2), 112-124.
[http://dx.doi.org/10.1593/neo.121638] [PMID: 23441126]
[12]
Wu, D.; Gao, Y.; Chen, L.; Qi, Y.; Kang, Q.; Wang, H.; Zhu, L.; Ye, Y.; Zhai, M. Anti-tumor effects of a novel chimeric peptide on S180 and H22 xenografts bearing nude mice. Peptides, 2010, 31(5), 850-864.
[http://dx.doi.org/10.1016/j.peptides.2010.01.007] [PMID: 20132854]
[13]
Wang, W.; Chen, X.; Li, T.; Li, Y.; Wang, R.; He, D.; Luo, W.; Li, X.; Wu, X. Screening a phage display library for a novel FGF8b-binding peptide with anti-tumor effect on prostate cancer. Exp. Cell Res., 2013, 319(8), 1156-1164.
[http://dx.doi.org/10.1016/j.yexcr.2013.02.007] [PMID: 23466786]
[14]
Wu, X.; Huang, H.; Wang, C.; Lin, S.; Huang, Y.; Wang, Y.; Liang, G.; Yan, Q.; Xiao, J.; Wu, J.; Yang, Y.; Li, X. Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation. Oncotarget, 2013, 4(10), 1819-1828.
[http://dx.doi.org/10.18632/oncotarget.1312] [PMID: 24142482]
[15]
Murugaiyan, G.; Saha, B. IL-27 in tumor immunity and immunotherapy. Trends Mol. Med., 2013, 19(2), 108-116.
[http://dx.doi.org/10.1016/j.molmed.2012.12.002] [PMID: 23306374]
[16]
Ogawa, C.; Liu, Y.J.; Kobayashi, K.S. Muramyl dipeptide and its derivatives: Peptide adjuvant in immunological disorders and cancer therapy. Curr. Bioact. Compd., 2011, 7(3), 180-197.
[http://dx.doi.org/10.2174/157340711796817913] [PMID: 22180736]
[17]
Chernysh, S.; Kozuharova, I. Anti-tumor activity of a peptide combining patterns of insect alloferons and mammalian immunoglobulins in naïve and tumor antigen vaccinated mice. Int. Immunopharmacol., 2013, 17(4), 1090-1093.
[http://dx.doi.org/10.1016/j.intimp.2013.10.014] [PMID: 24183654]
[18]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[19]
Balogh, J.; Victor, D., III; Asham, E.H.; Burroughs, S.G.; Boktour, M.; Saharia, A.; Li, X.; Ghobrial, R.M.; Monsour, H.P., Jr; Monsour, H.P. Hepatocellular carcinoma: A review. J. Hepatocell. Carcinoma, 2016, 3, 41-53.
[http://dx.doi.org/10.2147/JHC.S61146] [PMID: 27785449]
[20]
Liu, Y.; Chang, C-C.H.; Marsh, G.M.; Wu, F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur. J. Cancer, 2012, 48(14), 2125-2136.
[http://dx.doi.org/10.1016/j.ejca.2012.02.009] [PMID: 22405700]
[21]
Corey, K.E.; Pratt, D.S. Current status of therapy for hepatocellular carcinoma. Therap. Adv. Gastroenterol., 2009, 2(1), 45-57.
[http://dx.doi.org/10.1177/1756283X08100328] [PMID: 21180533]
[22]
Hu, J.; Chen, C.; Zhang, S.; Zhao, X.; Xu, H.; Zhao, X.; Lu, J.R. Designed antimicrobial and antitumor peptides with high selectivity. Biomacromolecules, 2011, 12(11), 3839-3843.
[http://dx.doi.org/10.1021/bm201098j] [PMID: 21955251]
[23]
Fadnes, B.; Uhlin-Hansen, L.; Lindin, I.; Rekdal, Ø. Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells. BMC Cancer, 2011, 11(1), 116.
[http://dx.doi.org/10.1186/1471-2407-11-116] [PMID: 21453492]
[24]
Segawa, K.; Nagata, S. An apoptotic ‘eat me’ signal: Phosphatidylserine exposure. Trends Cell Biol., 2015, 25(11), 639-650.
[http://dx.doi.org/10.1016/j.tcb.2015.08.003] [PMID: 26437594]
[25]
Gestin, M.; Dowaidar, M.; Langel, Ü. Uptake Mechanism of Cell-Penetrating Peptides; Springer: Cham, 2017, pp. 255-264.
[26]
Huang, Y.B.; Wang, X.F.; Wang, H.Y.; Liu, Y.; Chen, Y. Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework. Mol. Cancer Ther., 2011, 10(3), 416-426.
[http://dx.doi.org/10.1158/1535-7163.MCT-10-0811] [PMID: 21252288]
[27]
Yang, Q-Z.; Wang, C.; Lang, L.; Zhou, Y.; Wang, H.; Shang, D-J. Design of potent, non-toxic anticancer peptides based on the structure of the antimicrobial peptide, temporin-1CEa. Arch. Pharm. Res., 2013, 36(11), 1302-1310.
[http://dx.doi.org/10.1007/s12272-013-0112-8] [PMID: 23609760]
[28]
Najjar, K.; Erazo-Oliveras, A.; Brock, D.J.; Wang, T-Y.; Pellois, J-P. An l- to d-amino acid conversion in an endosomolytic analog of the cell-penetrating peptide TAT influences proteolytic stability, endocytic uptake, and endosomal escape. J. Biol. Chem., 2017, 292(3), 847-861.
[http://dx.doi.org/10.1074/jbc.M116.759837] [PMID: 27923812]
[29]
Papo, N.; Shai, Y. New lytic peptides based on the D, L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry, 2003, 42(31), 9346-9354.
[http://dx.doi.org/10.1021/bi027212o] [PMID: 12899621]
[30]
Roxin, Á.; Zheng, G. Flexible or fixed: A comparative review of linear and cyclic cancer-targeting peptides. Future Med. Chem., 2012, 4(12), 1601-1618.
[http://dx.doi.org/10.4155/fmc.12.75] [PMID: 22917248]
[31]
Rink, R.; Arkema-Meter, A.; Baudoin, I.; Post, E.; Kuipers, A.; Nelemans, S.A.; Akanbi, M.H.J.; Moll, G.N. To protect peptide pharmaceuticals against peptidases. J. Pharmacol. Toxicol. Methods, 2010, 61(2), 210-218.
[http://dx.doi.org/10.1016/j.vascn.2010.02.010] [PMID: 20176117]
[32]
Tørfoss, V.; Ausbacher, D.; Cavalcanti-Jacobsen, C. de A.; Hansen, T.; Brandsdal, B-O.; Havelkova, M.; Strøm, M.B. Synthesis of anticancer heptapeptides containing a unique lipophilic β(2,2) -amino acid building block. J. Pept. Sci., 2012, 18(3), 170-176.
[http://dx.doi.org/10.1002/psc.1434] [PMID: 22249949]
[33]
Li, J.; Koh, J-J.; Liu, S.; Lakshminarayanan, R.; Verma, C.S.; Beuerman, R.W. Membrane active antimicrobial peptides: Translating mechanistic insights to design. Front. Neurosci., 2017, 11, 73.
[http://dx.doi.org/10.3389/fnins.2017.00073] [PMID: 28261050]
[34]
Rosenberg, S.A.; Restifo, N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 2015, 348(6230), 62-68.
[http://dx.doi.org/10.1126/science.aaa4967] [PMID: 25838374]
[35]
Haney, E.F.; Hancock, R.E.W. Peptide design for antimicrobial and immunomodulatory applications. Biopolymers, 2013, 100(6), 572-583.
[http://dx.doi.org/10.1002/bip.22250] [PMID: 23553602]
[36]
Reeves, M.E.; Royal, R.E.; Lam, J.S.; Rosenberg, S.A.; Hwu, P.; Dissette, V.; Lee, E.; Glaspy, J.A.; McBride, W.H.; Economou, J.S. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res., 1996, 56(24), 5672-5677.
[PMID: 8971174]
[37]
Ribas, A.; Butterfield, L.H.; McBride, W.H.; Jilani, S.M.; Bui, L.A.; Vollmer, C.M.; Lau, R.; Dissette, V.B.; Hu, B.; Chen, A.Y.; Glaspy, J.A.; Economou, J.S. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res., 1997, 57(14), 2865-2869.
[PMID: 9230191]
[38]
Butterfield, L.H.; Ribas, A.; Dissette, V.B.; Amarnani, S.N.; Vu, H.T.; Oseguera, D.; Wang, H-J.; Elashoff, R.M.; McBride, W.H.; Mukherji, B.; Cochran, A.J.; Glaspy, J.A.; Economou, J.S. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res., 2003, 9(3), 998-1008.
[PMID: 12631598]
[39]
Bos, J.L. Ras oncogenes in human cancer: A review. Cancer Res., 1989, 49(17), 4682-4689.
[PMID: 2547513]
[40]
Jardetzky, T.S.; Lane, W.S.; Robinson, R.A.; Madden, D.R.; Wiley, D.C. Identification of self peptides bound to purified HLA-B27. Nature, 1991, 353(6342), 326-329.
[http://dx.doi.org/10.1038/353326a0] [PMID: 1922338]
[41]
Rahma, O.E.; Hamilton, J.M.; Wojtowicz, M.; Dakheel, O.; Bernstein, S.; Liewehr, D.J.; Steinberg, S.M.; Khleif, S.N. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J. Transl. Med., 2014, 12, 55.
[http://dx.doi.org/10.1186/1479-5876-12-55] [PMID: 24565030]
[42]
Berinstein, N.L. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: A review. J. Clin. Oncol., 2002, 20(8), 2197-2207.
[http://dx.doi.org/10.1200/JCO.2002.08.017] [PMID: 11956282]
[43]
Lesterhuis, W.J.; De Vries, I.J.M.; Schreibelt, G.; Schuurhuis, D.H.; Aarntzen, E.H.; De Boer, A.; Scharenborg, N.M.; Van De Rakt, M.; Hesselink, E.J.; Figdor, C.G.; Adema, G.J.; Punt, C.J. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res., 2010, 30(12), 5091-5097.
[PMID: 21187495]
[44]
Epping, M.T.; Wang, L.; Edel, M.J.; Carlée, L.; Hernandez, M.; Bernards, R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell, 2005, 122(6), 835-847.
[http://dx.doi.org/10.1016/j.cell.2005.07.003] [PMID: 16179254]
[45]
Conway, R.E.; Petrovic, N.; Li, Z.; Heston, W.; Wu, D.; Shapiro, L.H. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol. Cell. Biol., 2006, 26(14), 5310-5324.
[http://dx.doi.org/10.1128/MCB.00084-06] [PMID: 16809768]
[46]
Weber, J.S.; Vogelzang, N.J.; Ernstoff, M.S.; Goodman, O.B.; Cranmer, L.D.; Marshall, J.L.; Miles, S.; Rosario, D.; Diamond, D.C.; Qiu, Z.; Obrocea, M.; Bot, A. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J. Immunother., 2011, 34(7), 556-567.
[http://dx.doi.org/10.1097/CJI.0b013e3182280db1] [PMID: 21760528]
[47]
Buonaguro, L.; Mayer-Mokler, A.; Accolla, R.; Ma, Y.T.; Heidenreich, R.; Avallone, A.; Simeone, E.; Koenigsrainer, A.; Loeffler, M.; Gouttefangeas, C. HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients. J. Clin. Oncol., 2018, 36(15_suppl), TPS3135-TPS3135.
[48]
Karlsson-Parra, A.; Kovacka, J.; Heimann, E.; Jorvid, M.; Zeilemaker, S.; Longhurst, S.; Suenaert, P. Ilixadencel - an allogeneic cell-based anticancer immune primer for intratumoral administration. Pharm. Res., 2018, 35(8), 156.
[http://dx.doi.org/10.1007/s11095-018-2438-x] [PMID: 29904904]
[49]
Harzke, A.J.; Goodman, K.J.; Mullen, P.D.; Baillargeon, J. Heterogeneity in hepatitis B virus (HBV) seroprevalence estimates from U.S. adult incarcerated populations. Ann. Epidemiol., 2009, 19(9), 647-650.
[http://dx.doi.org/10.1016/j.annepidem.2009.04.001] [PMID: 19596205]
[50]
Nakatsura, T.; Yoshitake, Y.; Senju, S.; Monji, M.; Komori, H.; Motomura, Y.; Hosaka, S.; Beppu, T.; Ishiko, T.; Kamohara, H.; Ashihara, H.; Katagiri, T.; Furukawa, Y.; Fujiyama, S.; Ogawa, M.; Nakamura, Y.; Nishimura, Y. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem. Biophys. Res. Commun., 2003, 306(1), 16-25.
[http://dx.doi.org/10.1016/S0006-291X(03)00908-2] [PMID: 12788060]
[51]
Komori, H.; Nakatsura, T.; Senju, S.; Yoshitake, Y.; Motomura, Y.; Ikuta, Y.; Fukuma, D.; Yokomine, K.; Harao, M.; Beppu, T.; Matsui, M.; Torigoe, T.; Sato, N.; Baba, H.; Nishimura, Y. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin. Cancer Res., 2006, 12(9), 2689-2697.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-2267] [PMID: 16675560]
[52]
Nakatsura, T.; Komori, H.; Kubo, T.; Yoshitake, Y.; Senju, S.; Katagiri, T.; Furukawa, Y.; Ogawa, M.; Nakamura, Y.; Nishimura, Y. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin. Cancer Res., 2004, 10(24), 8630-8640.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-1177] [PMID: 15623647]
[53]
Nobuoka, D.; Yoshikawa, T.; Sawada, Y.; Fujiwara, T.; Nakatsura, T. Peptide vaccines for hepatocellular carcinoma. Hum. Vaccin. Immunother., 2013, 9(1), 210-212.
[http://dx.doi.org/10.4161/hv.22473] [PMID: 23442593]
[54]
Bidwell, G.L., III; Raucher, D. Therapeutic peptides for cancer therapy. Part I peptide inhibitors of signal transduction cascades. Expert Opin. Drug Deliv., 2009, 6(10), 1033-1047.
[http://dx.doi.org/10.1517/17425240903143745] [PMID: 19637980]
[55]
Sehdev, A.; Karrison, T.; Zha, Y.; Janisch, L.; Turcich, M.; Cohen, E.E.W.; Maitland, M.; Polite, B.N.; Gajewski, T.F.; Salgia, R.; Pinto, N.; Bissonnette, M.B.; Fleming, G.F.; Ratain, M.J.; Sharma, M.R. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother. Pharmacol., 2018, 82(2), 309-317.
[http://dx.doi.org/10.1007/s00280-018-3619-3] [PMID: 29948021]
[56]
Teesalu, T.; Sugahara, K.N.; Kotamraju, V.R.; Ruoslahti, E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl. Acad. Sci. USA, 2009, 106(38), 16157-16162.
[http://dx.doi.org/10.1073/pnas.0908201106] [PMID: 19805273]
[57]
Kaushal, V.; Mukunyadzi, P.; Dennis, R.A.; Siegel, E.R.; Johnson, D.E.; Kohli, M. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin. Cancer Res., 2005, 11(2 Pt 1), 584-593.
[PMID: 15701844]
[58]
Butterfield, L.H.; Koh, A.; Meng, W.; Vollmer, C.M.; Ribas, A.; Dissette, V.; Lee, E.; Glaspy, J.A.; McBride, W.H.; Economou, J.S. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res., 1999, 59(13), 3134-3142.
[PMID: 10397256]
[59]
Marr, A.K.; Gooderham, W.J.; Hancock, R.E. Antibacterial peptides for therapeutic use: Obstacles and realistic outlook. Curr. Opin. Pharmacol., 2006, 6(5), 468-472.
[http://dx.doi.org/10.1016/j.coph.2006.04.006] [PMID: 16890021]
[60]
Craik, D.J.; Fairlie, D.P.; Liras, S.; Price, D. The future of peptide-based drugs. Chem. Biol. Drug Des., 2013, 81(1), 136-147.
[http://dx.doi.org/10.1111/cbdd.12055] [PMID: 23253135]
[61]
Lau, J.L.; Dunn, M.K. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg. Med. Chem., 2018, 26(10), 2700-2707.
[http://dx.doi.org/10.1016/j.bmc.2017.06.052] [PMID: 28720325]
[62]
Drusano, G.L. Antimicrobial pharmacodynamics: Critical interactions of ‘bug and drug’. Nat. Rev. Microbiol., 2004, 2(4), 289-300.
[http://dx.doi.org/10.1038/nrmicro862] [PMID: 15031728]
[63]
Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic therapeutic peptides: Science and market. Drug Discov. Today, 2010, 15(1-2), 40-56.
[http://dx.doi.org/10.1016/j.drudis.2009.10.009] [PMID: 19879957]
[64]
Kaspar, A.A.; Reichert, J.M. Future directions for peptide therapeutics development. Drug Discov. Today, 2013, 18(17-18), 807-817.
[65]
Raucher, D.; Ryu, J.S. Cell-penetrating peptides: Strategies for anticancer treatment. Trends Mol. Med., 2015, 21(9), 560-570.
[http://dx.doi.org/10.1016/j.molmed.2015.06.005] [PMID: 26186888]
[66]
Böttger, R.; Hoffmann, R.; Knappe, D. Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum. PLoS One, 2017, 12(6), e0178943
[http://dx.doi.org/10.1371/journal.pone.0178943] [PMID: 28575099]
[67]
Sawada, Y.; Yoshikawa, T.; Nobuoka, D.; Shirakawa, H.; Kuronuma, T.; Motomura, Y.; Mizuno, S.; Ishii, H.; Nakachi, K.; Konishi, M.; Nakagohri, T.; Takahashi, S.; Gotohda, N.; Takayama, T.; Yamao, K.; Uesaka, K.; Furuse, J.; Kinoshita, T.; Nakatsura, T. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival. Clin. Cancer Res., 2012, 18(13), 3686-3696.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-3044] [PMID: 22577059]
[68]
Imaging the Tumor Response to the Tumor-Penetrating Peptide IRGD;
[69]
Kelly, G.J.; Kia, A.F-A.; Hassan, F.; O’Grady, S.; Morgan, M.P.; Creaven, B.S.; McClean, S.; Harmey, J.H.; Devocelle, M. Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells. Org. Biomol. Chem., 2016, 14(39), 9278-9286.
[http://dx.doi.org/10.1039/C6OB01815G] [PMID: 27722734]
[70]
Dąbrowska, K.; Kaźmierczak, Z.; Majewska, J.; Miernikiewicz, P.; Piotrowicz, A.; Wietrzyk, J.; Lecion, D.; Hodyra, K.; Nasulewicz-Goldeman, A.; Owczarek, B.; Górski, A. Bacteriophages displaying anticancer peptides in combined antibacterial and anticancer treatment. Future Microbiol., 2014, 9(7), 861-869.
[http://dx.doi.org/10.2217/fmb.14.50] [PMID: 25156375]
[71]
Jeong, W-J.; Bu, J.; Kubiatowicz, L.J.; Chen, S.S.; Kim, Y.; Hong, S. Peptide-nanoparticle conjugates: A next generation of diagnostic and therapeutic platforms? Nano Converg., 2018, 5(1), 38.
[http://dx.doi.org/10.1186/s40580-018-0170-1] [PMID: 30539365]
[72]
Colombo, G.; Curnis, F.; De Mori, G.M.S.; Gasparri, A.; Longoni, C.; Sacchi, A.; Longhi, R.; Corti, A. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J. Biol. Chem., 2002, 277(49), 47891-47897.
[http://dx.doi.org/10.1074/jbc.M207500200] [PMID: 12372830]
[73]
Murphy, E.A.; Majeti, B.K.; Barnes, L.A.; Makale, M.; Weis, S.M.; Lutu-Fuga, K.; Wrasidlo, W.; Cheresh, D.A. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl. Acad. Sci. USA, 2008, 105(27), 9343-9348.
[http://dx.doi.org/10.1073/pnas.0803728105] [PMID: 18607000]
[74]
Lesterhuis, W.J.; de Vries, I.J.M.; Schuurhuis, D.H.; Boullart, A.C.I.; Jacobs, J.F.M.; de Boer, A.J.; Scharenborg, N.M.; Brouwer, H.M.H.; van de Rakt, M.W.M.M.; Figdor, C.G.; Ruers, T.J.; Adema, G.J.; Punt, C.J. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: Antigen-specific T cell responses in DTH skin tests. Ann. Oncol., 2006, 17(6), 974-980.
[http://dx.doi.org/10.1093/annonc/mdl072] [PMID: 16600979]

Rights & Permissions Print Cite
Article Metrics
36
2
© 2024 Bentham Science Publishers | Privacy Policy